Therapeutic vaccines

A therapeutic vaccine is a vaccine which is administered after the disease or infection has already occurred.[1] The therapeutic vaccine works by activating immune system of the patient to fight towards infection. The difference in therapeutic vaccine and vaccine is that vaccines are administered to individuals as a precautionary measure to avoid the infection or disease while therapeutic vaccines are administered after the individual is already affected by the disease or infection. Therapeutic vaccine fights the existing infection in body rather then immunizing body for protection against future diseases and infections.[2] The therapeutic vaccines are mostly against viral infections. The patients affected with chronic viral infections are administered with therapeutic vaccines, as their immune system is not able to produce enough efficient antibodies.[3]

Provenge was the first therapeutic vaccine approved by FDA in 2010, which was developed by Dendreon. This therapeutic vaccine helped in treating prostate cancer where patients' own white blood cells (WBCs) were taken and treated with drug (vaccine) to train them to differentiate and fight cancer cells.[4]

Functionality

The therapeutic vaccines are new form of vaccines that are mostly being used for viral infections and various type of cancers. The therapeutic vaccine helps immune system to recognize foreign agent such as cancerous cell or the virus. The specific type of therapeutic vaccines includes Antigen vaccine. In case of antigen vaccines, the body is introduced to a foreign agent to activate the immune system so that it recognizes the agent when later encountered.[5]

Types

There are two types of therapeutic vaccines which are:

Autologous vaccines

Autologous means that 'derived from oneself' – An autologous vaccine is a personalized vaccine which is made from an individual’s own cells which could be either cancer cells or immune system cells.[6]

Allogenic vaccines

Allo means 'other'. Allogenic are majorly cancer vaccines which are made from non-self cancer cells which are grown in a lab.[7]

How therapeutic vaccines are different from vaccines

The concept of therapeutic vaccines is different. When a person hears the word vaccine, the thought of prevention against a certain disease comes into mind. However, therapeutic vaccines are method of treatment. Like any other vaccine, the immune system is regulated against a specific type of target. The main goal is to enhance the immune system activity. This type of vaccine can be employed for the treatment of various type of diseases and viral infections.[8] [9]

Efforts are being made to develop vaccines against various fatal diseases such as HIV, cancer, dengue fever, cholera, Diphtheria, etc.

Therapeutic vaccine against HIV

HIV is have no vaccine up til now, but therapeutic vaccine could be the breakthrough for HIV. Such vaccine would enhance affected patients immune system to fight the disease. Many researchers are trying to develop and test therapeutic HIV vaccines in order to slow the HIV progression to AIDS. People affected with HIV normally have HIV at undetectable level, which is detected by use of antiretroviral therapy (ART). If therapeutic vaccine for HIV worked out, it will save many lives.[10] There are many clinical trails being conducted for HIV therapeutic vaccine. Many clinical trials for therapeutic HIV vaccine are conducted by AIDSinfo, summaries for trails are available at their website.[11]

Therapeutic vaccine against cancer

Cancer is the major cause of deaths in the recent era. Cancer types and stages have enhanced with time and so has efforts to treat cancer. Currently, there are about 369 cancer vaccine studies ongoing all around the world.[12]

There are three cancer therapeutic vaccines which are approved by USA Food and Drug Administration, as following;

Provenge is Sipuleucel-T, a dendritic cell based vaccine for prostate cancer[13]. Bacillus Calmettle-Guerin (TheraCys) is a live attenuated vaccine which makes use of Mycobacterium bovis strain for bladder invasive cancer. Talimogene laherparepvec (T-VEC or Imlygic) is a vaccine for advanced oncolytic melanoma [14]

References
  1. "Therapeutic Vaccine - an overview: ScienceDirect Topics". www.sciencedirect.com. ScienceDirect. Retrieved 2019-11-26.
  2. "Preventive vaccine vs therapeutic vaccine | Fondation québecoise du Sida".
  3. Shimasaki, Craig (2014). "Understanding Biotechnology Product Sectors". Biotechnology Entrepreneurship. pp. 113–138. doi:10.1016/B978-0-12-404730-3.00009-9. ISBN 9780124047303.
  4. Gulley, James (2012). "Therapeutic vaccines The ultimate personalized therapy?". Human Vaccines & Immunotherapeutics. 9 (1): 219–221. doi:10.4161/hv.22106. PMC 3667942. PMID 22995839.
  5. Madan RA, Gulley JL, Fojo T, Dahut WL. (2010). "Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression". Oncologist. 15 (9): 969–975. doi:10.1634/theoncologist.2010-0129. PMC 3228037. PMID 20798195.CS1 maint: multiple names: authors list (link)
  6. Sondak, Vernon K.; Sabel, Michael S.; Mulé, James J. (1 April 2006). "Allogeneic and Autologous Melanoma Vaccines: Where Have We Been and Where Are We Going?". Clinical Cancer Research. 12 (7): 2337s–2341s. doi:10.1158/1078-0432.CCR-05-2555. PMID 16609055.
  7. Hanna, Michael G. (27 October 2014). "Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer". Human Vaccines & Immunotherapeutics. 8 (8): 1156–1160. doi:10.4161/hv.20740. PMC 3551893. PMID 22854664.
  8. "Treating Disease With Vaccines". WebMD. Missing or empty |url= (help)
  9. Dr. James W. Hodge, Dr. Chandan Guha, Dr. Jacques Neefjes (2008). "Synergizing Radiation Therapy and Immunotherapy for Curing Incurable Cancers: Opportunities and Challenges". Oncology (Williston Park). 22 (9): 1064–1084. PMC 3474236. PMID 18777956.CS1 maint: multiple names: authors list (link)
  10. Gina M Graziani, Jonathan B Angel (2015). "Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions". Journal of the International Aids Society. 18 (1): 20497. doi:10.7448/IAS.18.1.20497. PMC 4641978. PMID 26561337.
  11. Clinical trial number NCT01103687 for "Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults" at ClinicalTrials.gov
  12. Margaret E. Gatti-Mays, Jason M. Redman, Julie M. Collins, Marijo Bilusic. (2017). "Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations". Human Vaccines & Immunotherapeutics. 13 (11): 2561–2574. doi:10.1080/21645515.2017.1364322. PMC 5703410. PMID 28857666.CS1 maint: multiple names: authors list (link)
  13. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. (2010). "Sipuleucel-T immunotherapy for castration-resistant prostate cancer". New England Journal of Medicine. 363 (5): 411–22. doi:10.1056/NEJMoa1001294. PMID 20818862.CS1 maint: multiple names: authors list (link)
  14. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS (2015). "Talimogene laherparepvec improves durable response rate in patients with advanced melanoma". Journal of Clinical Oncology. 33 (25): 2780–88. doi:10.1200/JCO.2014.58.3377. PMID 26014293.CS1 maint: multiple names: authors list (link)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.